FDA Approves Mysterious 'Field Generator Positioning Devices' for Brains
Published Date: 11/26/2025
Rule
Summary
The FDA has officially classified the field generator positioning device as a low-risk, Class I device, making it easier and faster for patients to get access to this helpful technology. This change reduces red tape for manufacturers without compromising safety or effectiveness. The new classification took effect on November 26, 2025, but has been in place since July 10, 2020, so no new costs or delays are expected.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Easier patient access to device
If you are a patient, the FDA has classified the field generator positioning device as Class I (general controls), and says this will enhance patients' access by reducing regulatory burdens. The final order is effective November 26, 2025, and the classification was applicable on July 10, 2020.
Manufacturers face lower premarket burden
If you manufacture or import this device, FDA placed the field generator positioning device in Class I (general controls) and states devices in this type are exempt from premarket notification (510(k)) under section 510(l)(1), except when the device is of substantial importance in preventing impairment of human health or presents a potentially unreasonable risk. FDA says this classification reduces regulatory burdens; the final order is effective November 26, 2025 and was applicable on July 10, 2020.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16666, Determination That ANSAID (Flurbiprofen) Tablets, 50 Milligrams and 100 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that ANSAID (flurbiprofen) tablets, 50 milligrams (mg) and 100 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for flurbiprofen tablets, 50 mg and 100 mg, if all other legal and regulatory requirements are met.
2026-16648, Determination That LASIX (Furosemide) Tablets, 20 Milligrams, 40 Milligrams, and 80 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that LASIX (furosemide) tablets, 20 milligrams (mg), 40 mg, and 80 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.
2026-16650, Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments
The Food and Drug Administration (FDA, the Agency, or we) is hosting a public meeting to discuss proposed recommendations for the reauthorization of the Prescription Drug User Fee Act (PDUFA) for fiscal years (FYs) 2028 through 2032. PDUFA authorizes FDA to collect user fees to support the process for the review of human drug applications. The current legislative authority for PDUFA expires in September 2027. At that time, new legislation will be required for FDA to continue collecting prescription drug user fees in future fiscal years. Following discussions with the regulated industry and periodic consultations with public stakeholders, the Federal Food, Drug, and Cosmetic Act (the FD&C Act) directs FDA to publish the recommendations for the reauthorized program in the Federal Register, hold a meeting at which the public may present its views on such recommendations, and provide for a period of 30 days for the public to provide written comments on such recommendations. FDA will then consider such public views and comments and revise such recommendations, as necessary.
Previous / Next Documents
Previous: 2025-21217, Medical Devices; Gastroenterology-Urology Devices; Classification of the Anchored Esophageal Sheath
The FDA is officially classifying the anchored esophageal sheath as a Class II medical device with special safety rules. This change helps make sure the device is safe and effective while making it easier for patients to get access to this helpful technology. The new rules took effect on November 26, 2025, and could reduce some regulatory hurdles for manufacturers.
Next: 2025-21242, Extending Deadline for Debtor To Request a Waiver
The VA is giving veterans more time—up to one year instead of 180 days—to ask for a waiver on debts related to benefits. This change, effective January 26, 2026, helps reduce stress by giving veterans extra breathing room to handle their debt issues. It doesn’t cost veterans extra money but makes the process friendlier and fairer.